The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Herrick, A. L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol. 8, 469–479 (2012).
Flavahan, N. A. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat. Rev. Rheumatol. 11, 146–158 (2015).
Freedman, R. R. & Mayes, M. D. Familial aggregation of primary Raynaud’s disease. Arthritis Rheum. 39, 1189–1191 (1996).
Maudrell, A. & Proudman, S. M. in Raynaud’s Phenomenon: A Guide to Pathogenesis and Treatment 1st edn (eds Wigley, F. M. et al.) Ch. 3 (Springer New York, 2015).
Hartmann, S. et al. ADRA2A and IRX1 are putative risk genes for Raynaud’s phenomenon. Nat. Commun. 14, 6156 (2023).
Yengo, L. et al. A saturated map of common genetic variants associated with human height. Nature 610, 704–712 (2022).
Abdulle, A. E. et al. Low body weight and involuntary weight loss are associated with Raynaud’s phenomenon in both men and women. Scand. J. Rheumatol. 50, 153–160 (2021).
Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
Ochoa, D. et al. Open Targets Platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. 49, D1302–D1310 (2021).
Coffman, J. D. Raynaud’s phenomenon. An update. Hypertension 17, 593–602 (1991).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.L.H. has received consultancy fees from Arena, Boehringer Ingelheim, Camurus, Galderma and Gesynta Pharma, speaker fees from Janssen and research funding from Gesynta Pharma. G.O. declares no competing interests.
Rights and permissions
About this article
Cite this article
Herrick, A.L., Orozco, G. Raynaud phenomenon: from GWAS to drug repurposing. Nat Rev Rheumatol 20, 139–140 (2024). https://doi.org/10.1038/s41584-024-01076-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-024-01076-x
